Cara taps Korean firm as first licensee for its lead analgesic
This article was originally published in Scrip
Executive Summary
The US venture Cara Therapeutics has struck the first licensing deal for its lead product candidate CR845, allying with Chong Kun Dang Pharmaceutical (CKD) for the development and marketing of the analgesic in South Korea.
You may also be interested in...
Cara Ready To Move Into Pivotal Studies In ESRD Pruritus
With a successful end-of-Phase II meeting with FDA concluded, Cara moves closer to bringing the first drug to market for pruritus in ESRD patients on dialysis.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: easy alliances rather than big deals the focus at JP Morgan; multiple company roundups from JPM; and Lilly braces for impact of US CMS decision on Aduhelm.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: new mRNA vaccine deal for Pfizer and BioNTech; court ruling helps Novartis’s Gilenya; first cut-price generic Paxlovid launched; breaking down BridgeBio’s Phase III failure; and a look at gene editing companies to watch at JP Morgan.